이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Pain Sensitivity, Alcohol-Induced Analgesia, and Heavy Drinking in Individuals With Opioid Use Disorder

2026년 11월 16일 업데이트: Stephanie M Gorka, PhD, Ohio State University

The goal of this clinical trial is to examine whether individuals with co-occurring opioid use disorder and alcohol use (OUD+ALC) experience heightened pain sensitivity, pain-related negative affect, and greater alcohol reinforcement compared with alcohol-only (ALC) or opioid-only (OUD-ALC) users.

The main questions it aims to answer are:

  • Aim 1. Do individuals with OUD+ALC experience increased pain and pain-related negative affect during periods of sobriety relative to mono-users of alcohol (ALC only) and opioids (OUD-ALC)?
  • Aim 2. Do individuals with OUD+ALC experience greater alcohol-induced analgesia and alcohol reinforcement compared with mono-users of alcohol (ALC only) and opioids (OUD-ALC)?

Participants will:

  • Complete a screening session
  • Complete one lab session including a comprehensive assessment battery involving multimodal assessments of pain during sobriety
  • Complete two experimental lab sessions that will include intravenous (IV) administration of either 80mg% alcohol or placebo (saline), order counterbalanced, to measure alcohol's acute effects on pain and pain-related negative affect

연구 개요

연구 유형

중재적

등록 (추정된)

90

단계

  • 초기 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Ohio
      • Columbus, Ohio, 미국, 43210
        • 모병
        • Ohio State University
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

21년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

ALC Only Group:

  • 21-65 years old
  • Required to meet NIAAA criteria for heavy drinking (Male: Consuming 5 or more drinks on any day or 15 or more per week; Female: consuming 4 or more on any day or 8 or more drinks per week)

OUD + ALC Group:

  • 21-65 years old
  • Required to meet NIAAA criteria for heavy drinking (Male: Consuming 5 or more drinks on any day or 15 or more per week; Female: consuming 4 or more on any day or 8 or more drinks per week)
  • Meet DSM-5 criteria for current opioid use disorder (OUD)
  • Report using recreational opioids at least weekly (past month)

OUD-ALC Group:

  • 21-65 years old
  • Meet DSM-5 criteria for current OUD
  • Report using recreational opioids at least weekly (past month)
  • Meet "light drinking" criteria (consuming equal to or less than 4 drinks per week for women or consuming equal to or less than 5 drinks per week for men)
  • Report at least 1 but no more than 3 binge episodes over the past 12 months

Exclusion Criteria:

  • Serious medical problems
  • Current medical or psychiatric conditions requiring medication for which alcohol is contraindicated (including prescription opioids)
  • Any serious medical problems
  • Sensitivity or allergy to alcohol
  • Body weight < 110 or > 210 lbs for alcohol administration
  • Injury, trauma, nerve/tissue damage, or deformity prohibiting sensory testing
  • Moderate to severe substance use disorders other than alcohol use disorder (AUD) or OUD
  • Current severe mental illness, including mania or psychosis
  • Currently seeking inpatient/intensive treatment for addictive behaviors
  • Pregnant or nursing and unwilling to take measures to avoid becoming pregnant during the study (females)
  • Chronic pain requiring ongoing pain management within the past three months.
  • Clinically significant alcohol or opioid withdrawal symptoms the day of the lab sessions, defined as a score >10 on the Clinical Institute Withdrawal Assessment of Alcohol Scale Revised (CIWA-Ar) or a score >12 on the Clinical Opioid Withdrawal Scale (COWS)
  • Positive alcohol breath test or opioid urine screen the day of the experimental lab sessions to avoid the potential for alcohol-opioid interactions.
  • Smoking more than 6 cigarettes per day (or alternative form equivalent)
  • Not fluent in English

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 기초 과학
  • 할당: 무작위화되지 않음
  • 중재 모델: 크로스오버 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
다른: Alcohol (ALC) Only Group

Participants in this group will be required to meet the National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria for heavy drinking (Male: Consuming 5 or more drinks on any day or 15 or more per week; Female: consuming 4 or more on any day or 8 or more drinks per week).

Participants will receive 80 mg% intravenous alcohol and saline.

Participants receive placebo (saline) intravenously.

다른: Opioid Use Disorder (OUD) + ALC Group

Participants in this group will be required to 1) Meet the National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria for heavy drinking (Male: Consuming 5 or more drinks on any day or 15 or more per week; Female: consuming 4 or more on any day or 8 or more drinks per week); 2) Meet DSM-5 criteria for current OUD and; 3) Report using recreational opioids at least weekly (past month).

Participants will receive 80 mg% intravenous alcohol and saline.

Participants receive placebo (saline) intravenously.

다른: OUD-ALC Group

Participants in this group will be required to 1) Meet DSM-5 criteria for current OUD; 2) Report using recreational opioids at least weekly (past month); 3) Meet "light drinking" criteria (consuming less than or equal to 4 alcoholic drinks per week (female) or less than or equal to 5 alcoholic drinks (men) and; 4) Report at least 1 but no more than 3 binge episodes over the past 12 months.

Participants will receive 80 mg% intravenous alcohol and saline.

Participants receive placebo (saline) intravenously.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Pain intensity during the pressure task, measured using a visual analog scale (VAS)
기간: Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)

Pain intensity will be reported during the pressure task administered during each of the three laboratory sessions (Baseline, Placebo, and Alcohol). Participants will rate their perceived pain intensity using a numerical rating scale ranging from 0-100.

Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)
Pain pressure threshold during the pressure task
기간: Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)

Pain pressure threshold is estimated by averaging reports across the different runs of the pressure task that is administered at all three lab sessions.

Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)
Startle eyeblink potentiation during the anticipation task
기간: Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)

Startle eyeblink potentiation will be collected during the anticipation task that is administered at all three lab sessions. Startle is a cross-species index of aversive reactivity.

Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)
Self-reported affect during the anticipation task
기간: Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)

At the end of the anticipation task, participants will rate how intense, arousing, and anxiety-provoking the task was on a 1-to-10 scale, with 1 indicating low intensity, arousal, or anxiety and 10 indicating high intensity, arousal, or anxiety.

Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)
Subjective affective response to alcohol in the lab
기간: Placebo and Alcohol sessions (Visits 2 and 3), approximately 7 days apart.

Participants will complete the Profile of Mood States (POMS) throughout the placebo and alcohol administration protocols. The individual mood states will be examined and compared across sessions. Higher scores on each POMS subscale indicate a greater degree of the corresponding mood state, while lower scores indicate a lesser degree of that mood state.

Placebo and Alcohol sessions (Visits 2 and 3), approximately 7 days apart.

2차 결과 측정

결과 측정
측정값 설명
기간
Subjective effects of alcohol in the lab
기간: Placebo and Alcohol sessions (Visits 2 and 3), approximately 7 days apart.

Participants will rate the degree to which they "feel", "like", and "want more" of the infused substance on a visual analog scale ranging from 0 to 100. The "like" and "want more" scales will serve as the primary measures of alcohol liking and wanting, respectively.

Placebo and Alcohol sessions (Visits 2 and 3), approximately 7 days apart.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 11월 12일

기본 완료 (추정된)

2028년 8월 1일

연구 완료 (추정된)

2028년 8월 1일

연구 등록 날짜

최초 제출

2026년 9월 16일

QC 기준을 충족하는 최초 제출

2026년 10월 19일

처음 게시됨 (실제)

2026년 10월 26일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 19일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 16일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

De-identified data, including startle eyeblink and behavior, from this project will be submitted to the The National Institute on Alcohol Abuse and Alcoholism Data Archive (NIAAADA) at the subject level along with appropriate supporting documentation to enable efficient use of the data by the research community. We will follow instructions as discussed in the NDA Data Sharing Terms and Conditions.

IPD 공유 기간

The data will be submitted biannually.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다